Bacteremia Clinical Trial
Official title:
Establish Quantitative PCR to Measure Bacteria Load of the VRE Bacteremia
The investigators hypothesized that quantitative PCR can be used in VRE bacteremia outcome
monitoring. Vancomycin-resistant enterococci (VRE) was first found in 1988 and has become an
important healthcare-associated pathogen due to rapid spread, limited options for therapy
and the possibility of transferring vancomycin resistance to more virulent pathogens. VRE
infections not only contribute to more hospital cost and longer length of hospital stay, but
also higher attributable mortality compared to those caused by vancomycin susceptible
enterococci. Two different meta-analyses have shown that vancomycin resistance is an
independent predictor of death among patients with enterococcal bloodstrem infections
(BSIs). Despite this, few effective antibiotics are approved by the US Food and Drug
Administration for the treatment of serious VRE infections. Though several studies have
conducted to find the possible mortality predictors, but none has used bacterial load as a
marker.
Schonheyder et al. have used semiquantitative culture, and demonstrate the relationship
between high bacterial load and mortality. However, it may take more than two days before
culture result available, and the sensitivity of culture is greatly affected by
antimicrobial treatment. Real-time PCR has been demonstrate good performance in early
detection of bacteremia, and theoretically is less affected by antimicrobial usage. However,
using quantitative real-time PCR to quantify VRE in blood has not been explored, yet.
The objective of this study is to establish a quantitative method to measure the amounts of
VRE in blood using the VRE specific van gene. And test the hypothesis that higher VRE load
in blood results in higher mortality among patients with VRE BSIs.
Primers and probe of VRE Real-time PCR will be constructed first. The investigators will
prospective enroll patient with VRE bacteremia. Clinical data and outcome will be monitored.
Bacteria load of VRE bacteremia will be measured via established real-time PCR. The outcome
and the association of bacteria load of VRE bacteremia will be analyzed.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |